Mohamed Chebaclo
Cardiovascular Disease · Grand Forks, NDNPI 1386708931
Payments from drug & device makers
What this record shows
19 manufacturers reported payments, led by Medtronic at 33.8% of the total. Reporting peaked in 2023 at $1,979 and has fallen 96.8% since, to $62 in 2025.
Across 112 payments — averaging $61.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$2K
- Johnson & Johnson$920
- E.r. Squibb & Sons, L.L.C.$289
- Amgen$267
- Novartis$227
- plus $839 from 13 others
What the payments were for
- Travel & lodging$3,50651%
- Food & beverage$3,34849%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 18 | $2,318 |
| Abbott | 10 | $1,994 |
| Johnson & Johnson | 17 | $920 |
| E.r. Squibb & Sons, L.L.C. | 11 | $289 |
| Amgen | 9 | $267 |
| Novartis | 7 | $227 |
| AstraZeneca | 8 | $150 |
| Daiichi Sankyo Inc. | 1 | $143 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $127 |
| Sanofi-aventis U.S. LLC | 7 | $102 |
| Edwards Lifesciences | 1 | $60 |
| Getinge USA Sales, LLC | 1 | $51 |
| Lundbeck LLC | 4 | $51 |
| Livanova USA, Inc. | 1 | $39 |
| Boehringer Ingelheim | 3 | $37 |
| Scpharmaceuticals Inc. | 2 | $34 |
| Novo Nordisk | 1 | $21 |
| United Therapeutics Corporation | 1 | $13 |
| Alnylam Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,853 in reported general payments places this provider in the 70th percentile of 35 cardiovascular disease providers in North Dakota.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 167 | $210,389 |
| XareltoRivaroxaban | 30 | $36,774 |
| Repatha SureclickEvolocumab | 13 | $18,207 |
| BrilintaTicagrelor | 18 | $9,588 |
| Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid | 15 | $5,816 |
| Metoprolol Succinate | 438 | $5,053 |
| Ranolazine ErRanolazine | 40 | $4,067 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 36 | $3,886 |
| Atorvastatin Calcium | 295 | $2,387 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 163 | $1,919 |
| ClopidogrelClopidogrel Bisulfate | 185 | $1,704 |
| Nitroglycerin | 69 | $1,264 |
| Amlodipine Besylate | 171 | $1,237 |
| Rosuvastatin Calcium | 105 | $1,170 |
| Nitroglycerin PatchNitroglycerin | 25 | $1,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $920 | $36,77430 claims |
| AstraZenecaBrilinta | $150 | $9,58818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 35 cardiovascular disease providers in North Dakota.
Other cardiovascular disease in Grand Forks
- Noah ChelliahGrand Forks$115K
- Hussain BasrawalaGrand Forks$40K
- Mikhail KirnusGrand Forks$16K
- Rabeea AboufakherGrand Forks$14K
- Puvanalingam AyyaduraiGrand Forks$3K
- Abdelhamid AhmedGrand Forks$17
- Beng Loong Isaac TeaMinot$42K
- Thomas HaldisFargo$37K
- Matthew GlogozaFargo$36K
- Timothy PansegrauBismarck$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.